Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 of Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of Drs. Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D. to Certain Committees of our Board of Directors

As described in the Current Report on Form 8-K we filed on February 14, 2017, on February 13, 2017, the board of directors, or the Board, of Arena Pharmaceuticals, Inc., or the Company, appointed Drs. Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D., to serve as directors. At the time of the filing, the Board had not yet determined the committees of the Board on which Drs. Dallas, Fetzer and Neil would serve.

At the Board’s meeting on June 13, 2017, the Board appointed members to the Board’s standing committees, effective immediately. Dr. Dallas was appointed to the Board’s Compensation Committee and Corporate Governance and Nominating Committee. Dr. Fetzer was appointed to the Board’s Compensation Committee. Dr. Neil was appointed to the Board’s Corporate Governance and Nominating Committee.

In connection with their committee appointments, effective July 1, 2017, Drs. Dallas, Fetzer, and Neil are each eligible to receive retainers in connection with their service on committees of the Board. For Compensation Committee service, a quarterly retainer of $1,875 applies. For Corporate Governance and Nominating Committee service, a quarterly retainer of $1,250 applies.

About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).